Role of 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) in autoimmune hypophysitis: a case report

Ziren Kong, Yu Wang, Wenbin Ma, Xin Cheng, Ziren Kong, Yu Wang, Wenbin Ma, Xin Cheng

Abstract

Background: Autoimmune hypophysitis is a rare disease characterized by the infiltration of lymphocytic cells into the pituitary gland. 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) positron emission tomography (PET) are well-established and emerging techniques, respectively, which may aid in the diagnosis and classification of autoimmune hypophysitis.

Case presentation: Here, we report a 40-year-old female diagnosed with central diabetes insipidus and multiple pituitary hormone deficiencies, and MRI revealed homogeneous signals in the pituitary gland as well as thickened in the pituitary stalk. FDG PET localized the pituitary and pituitary stalk lesions and displayed an SUVmax of 5.5. FDS, a sensitive radiotracer for bacterial infections but remains unproven under aseptic inflammation, also demonstrated elevated radioactivity, with an SUVmax of 1.1 at 30 min and 0.73 at 120 min. Transnasal biopsy suggested a diagnosis of autoimmune hypophysitis, and the patient displayed radiological and clinical improvement after treatment with glucocorticoids and hormone replacement.

Conclusions: Autoimmune hypophysitis can display elevated FDG uptake, which aids in the localization of the lesions. In addition to revealing bacterial infection specifically, FDS can also accumulate under autoimmune conditions, suggesting that it could serve as a potential radiotracer for both bacterial and aseptic inflammation.

Trial registration: The patient was enrolled in study NCT02450942 (clinicaltrials.gov, Registered May 21, 2015).

Keywords: Autoimmune hypophysitis; Case report; FDG; FDS; PET.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Contrast-enhanced T1-weighted and T2-weighted MR images of the lesions. a-b. Pituitary with a size of 18.6 mm × 8.2 mm × 9.9 mm displayed a contrast-enhanced signal, and a lesion with a size of 6.5 mm × 5.2 mm × 4.6 mm and a relative hypointense contrast-enhanced signal was located (arrow noted). The pituitary stalk with a size of 5.1 mm × 1.7 mm showed an isointense contrast-enhanced signal (arrowhead noted) compared with the normal pituitary stalk. c. The pituitary lesion presented a hyperintense T2-weighted signal (arrow noted), and the thickened pituitary stalk exhibited an isointense T2-weighted signal in comparison with the normal pituitary. d-f. Contrast-enhanced T1-weighted and T2-weighted MR images of the lesions 3 years after surgery. The pituitary displayed postsurgical changes with no significant hypointense contrast-enhanced signal or hyperintense T2-weighted signal, and the pituitary stalk thickness was reduced (3.0 mm × 2.0 mm, arrowhead noted) compared with pretreatment MRI
Fig. 2
Fig. 2
FDG and FDS activity of the lesions. a-d. Both the pituitary and pituitary stalk lesions displayed FDG activity with an SUVmax of 5.5 after 40 min of radiotracer injection. e-f. Both lesions displayed FDS activity with a SUVmax of 1.1 at 30 min after FDS injection; in comparison, the SUVmax of the normal brain tissue was 0.15, and the T/N ratio was 7.3. g-h. The lesions remained FDS active after 120 min of FDS administration with a SUVmax of 0.73; the SUVmax of the normal brain and the T/N ratio were 0.08 and 9.1, respectively
Fig. 3
Fig. 3
FDG and FDS activity in a patient with a normal pituitary. a-d. Both the pituitary and pituitary stalks did not display FDG activity. e-h. FDS was also not absorbed in normal pituitary and pituitary stalks

References

    1. Sautner D, Saeger W, Ludecke DK, Jansen V, Puchner MJ. Hypophysitis in surgical and autoptical specimens. Acta Neuropathol. 1995;90(6):637–644. doi: 10.1007/BF00318578.
    1. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev. 2005;26(5):599–614. doi: 10.1210/er.2004-0011.
    1. Johnston PC, Chew LS, Hamrahian AH, Kennedy L. Lymphocytic infundibulo-neurohypophysitis: a clinical overview. Endocrine. 2015;50(3):531–536. doi: 10.1007/s12020-015-0707-6.
    1. Chiloiro S, Tartaglione T, Angelini F, et al. An overview of diagnosis of primary autoimmune Hypophysitis in a prospective single-center experience. Neuroendocrinology. 2017;104(3):280–290. doi: 10.1159/000446544.
    1. Basu S. Personalized versus evidence-based medicine with PET-based imaging. Nat Rev Clin Oncol. 2010;7(11):665–668. doi: 10.1038/nrclinonc.2010.121.
    1. Glaudemans AW, de Vries EF, Galli F, Dierckx RA, Slart RH, Signore A. The use of (18) F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:623036. doi: 10.1155/2013/623036.
    1. Balink H, Bennink RJ, Veeger NJ, van Eck-Smit BL, Verberne HJ. Diagnostic utility of (18) F-FDG PET/CT in inflammation of unknown origin. Clin Nucl Med. 2014;39(5):419–425. doi: 10.1097/RLU.0000000000000423.
    1. Kong Z, Jiang C, Zhu R, et al. (18) F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma. NeuroImage. Clinical. 2019;23:101912. doi: 10.1016/j.nicl.2019.101912.
    1. Yao S, Xing H, Zhu W, et al. Infection imaging with (18) F-FDS and first-in-human evaluation. Nucl Med Biol. 2016;43(3):206–214. doi: 10.1016/j.nucmedbio.2015.11.008.
    1. Weinstein EA, Ordonez AA, DeMarco VP, et al. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Sci Transl Med. 2014;6(259):259ra146. doi: 10.1126/scitranslmed.3009815.
    1. Li ZB, Wu Z, Cao Q, et al. The synthesis of 18F-FDS and its potential application in molecular imaging. Mol Imaging Biol. 2008;10(2):92–98. doi: 10.1007/s11307-007-0125-0.
    1. Iglesias P, Cardona J, Diez JJ. The pituitary in nuclear medicine imaging. Eur J Intern Med. 2019;68:6–12. doi: 10.1016/j.ejim.2019.08.008.
    1. Wang H, Hou B, Lu L, et al. PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study. J Nucl Med. 2018;59(3):523–528. doi: 10.2967/jnumed.117.191916.
    1. Obert J, Vercellino L, Van Der Gucht A, et al. (18) F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging. 2017;44(4):598–610. doi: 10.1007/s00259-016-3521-3.
    1. Ding Y, Wu S, Xu J, Wang H, Ma C. Pituitary 18F-FDG uptake correlates with serum TSH levels in thyroid cancer patients on 18F-FDG PET/CT. Nucl Med Commun. 2019;40(1):57–62. doi: 10.1097/MNM.0000000000000940.
    1. Ju H, Zhou J, Pan Y, Lv J, Zhang Y. Evaluation of pituitary uptake incidentally identified on (18) F-FDG PET/CT scan. Oncotarget. 2017;8(33):55544–55549. doi: 10.18632/oncotarget.15417.
    1. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncology. 2018;4(2):173–182. doi: 10.1001/jamaoncol.2017.3064.
    1. van der Hiel B, Blank CU, Haanen JB, Stokkel MP. Detection of early onset of hypophysitis by (18) F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clin Nucl Med. 2013;38(4):e182–e184. doi: 10.1097/RLU.0b013e3182639765.
    1. Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in Ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24(1):111–115. doi: 10.1016/j.acra.2016.08.005.
    1. Mekki A, Dercle L, Lichtenstein P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer (Oxford, England : 1990) 2018;96:91–104. doi: 10.1016/j.ejca.2018.03.006.
    1. Werner RA, Wakabayashi H, Chen X, et al. Functional renal imaging with 2-Deoxy-2-(18) F-Fluorosorbitol PET in rat models of renal disorders. J Nucl Med. 2018;59(5):828–832. doi: 10.2967/jnumed.117.203828.
    1. Gao L, Guo X, Tian R, et al. Pituitary abscess: clinical manifestations, diagnosis and treatment of 66 cases from a large pituitary center over 23 years. Pituitary. 2017;20(2):189–194. doi: 10.1007/s11102-016-0757-7.

Source: PubMed

3
Iratkozz fel